Over the past 18 months, Large Molecule Injectable Drugs industry trends have been reshaped by a surge in bi-specific antibody alliances, headlined by Amgen and Horizon Therapeutics forging a co-commercialisation pact for a late-stage ocular biologic projected to reach $2.3 B in peak sales. Pfizer’s $116 B acquisition of Seagen closed in October 2023, instantly creating the largest ADC-based injectable pipeline while triggering parallel CDMO capacity expansion at Thermo Fisher’s Greenville campus to keep fill-finish lines ready. On the regulatory front, the FDA’s final 2024 guidance on low-volume parenteral manufacturing now allows real-time TOC (total organic carbon) testing, trimming batch release by 8–12 days and accelerating biosimilar launches such as Coherus’ pegfilgrastim biosimilar (Udenyca® AMP). Venture funding has pivoted toward AI-driven self-administration devices: Biolinq secured $58 M Series B for its microneedle-based biosensor patch targeting weekly GLP-1 injectables, while Enable Injections raised $215 M to scale wearable large-volume bolus delivery ahead of 2025 obesity-care demand. Collectively, these moves signal a shift from hospital-centric administration to patient-controlled, at-home therapy, forcing pharma firms to bundle digital nurse-support services into every commercial launch plan.
